Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks

NIAID Data Ecosystem2026-03-07 收录

肿瘤药物一期临床

剂量递增研究

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2110616 数据链接链接失效反馈

官方服务：

资源简介：

Phase I Study of PM01183 in Non-Colorectal Cancer Patients to determine the recommended dose (RD) of PM01183.

创建时间：

2011-11-15

Supplementary Material for: Accelerated Dose Escalation with Three Injections of an Aluminum Hydroxide-Adsorbed Allergoid Preparation of Six Grasses Is Safe for Patients with Moderate to Severe Allergic Rhinitis

过敏原免疫治疗安全性

剂量递增研究

Only few data on safety during high-dose, accelerated escalation schedules during subcutaneous allergen immunotherapy (AIT) are available. The aim of this study was to assess the safety and tolerabili

NIAID Data Ecosystem80

sj-tgz-1-ctj-10.1177_17407745231188443 – Supplemental material for Randomized controlled dose-escalation design to evaluate the safety of a novel pharmacological cardiopulmonary resuscitation strategy

剂量递增研究

心脏复苏药物

Supplemental material, sj-tgz-1-ctj-10.1177_17407745231188443 for Randomized controlled dose-escalation design to evaluate the safety of a novel pharmacological cardiopulmonary resuscitation strategy

DataCite Commons2024-08-28 更新60

Supplementary Material – Phase I/Ib Dose-Escalation Study of Avelumab in Chinese Patients With Advanced Solid Tumors

肿瘤免疫治疗

剂量递增研究

Supplementary Table 1. Antitumor activity Phase I/Ib Dose-Escalation Study of Avelumab in Chinese Patients With Advanced Solid Tumors

DataCite Commons2024-02-08 更新50

A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors

抗肿瘤药物安全性

剂量递增研究

The goal of this clinical trial is to evaluate the safety of TOS-358 in adults with select solid tumors who meet study enrollment criteria. The main questions it aims to answer are: 1. what is the max

NIAID Data Ecosystem60

Interim analyses and non-comparative efficacy analysis for primary (day 210) and secondary (day 30) end points.

剂量递增研究

临床试验效果分析

Intention-to-Treat and Per-Protocol complete-case analysis populations were identical at day 30 & day 210. Exact binomial 95% confidence interval (CI). One-sided 97.5% confidence interval. Multiple ve

NIAID Data Ecosystem60

Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks

资源简介：

相关数据集